Lyr

Lyra Therapeutics Announces Positive Topline Results of Pharmacokinetic Study of LYR-210 in Patients with Chronic Rhinosinusitis

Retrieved on: 
Wednesday, June 30, 2021
Lyra, Lyr, Pharmacokinetics, Sinusitis, Clinical medicine, Natural sciences

(Nasdaq: LYRA), a clinical-stage therapeutics company leveraging its proprietary XTreo platform to enable precise, sustained, and local delivery of medications to the ear, nose and throat (ENT) passages and other diseased tissues, today announced positive topline results from the companys pharmacokinetic (PK) study of LYR-210.

Key Points: 
  • (Nasdaq: LYRA), a clinical-stage therapeutics company leveraging its proprietary XTreo platform to enable precise, sustained, and local delivery of medications to the ear, nose and throat (ENT) passages and other diseased tissues, today announced positive topline results from the companys pharmacokinetic (PK) study of LYR-210.
  • The clinical study was a 56-day open label, multi-center, U.S. study of the PK and safety of LYR-210 in adult subjects with chronic rhinosinusitis (CRS).
  • MF blood plasma levels observed during the PK study support LYR-210s ability to deliver consistent and steady dosing over the entire treatment period.
  • This was the first U.S. study of LYR-210 and it was fully enrolled across four sites in 11 weeks.

Lyra Therapeutics Announces Positive Outcome of End-of-Phase 2 Meeting with the FDA for LYR-210 for the Treatment of Chronic Rhinosinusitis

Retrieved on: 
Tuesday, June 8, 2021
FDA, Health, Surgery, Clinical trials, General Health, Pharmaceutical, Lyr, Food and Drug Administration, Health

Lyra and the FDA established key elements of the Phase 3 program to support a 505(b)(2) new drug application for LYR-210 for the treatment of CRS.

Key Points: 
  • Lyra and the FDA established key elements of the Phase 3 program to support a 505(b)(2) new drug application for LYR-210 for the treatment of CRS.
  • Both studies will evaluate a 7500g dose of LYR-210, and additional key clinical aspects of the studies will also be the same.
  • Following our successful End of Phase 2 meeting with the FDA, we believe that we have a clear path forward to advance LYR-210s clinical development for the treatment of CRS.
  • Lyra will host a conference call and live webcast today, Tuesday, June 8, 2021, at 5:00 p.m.

Lyra Therapeutics and LianBio Announce Strategic Partnership and Exclusive License Agreement to Develop and Commercialize LYR-210 in Greater China and Other Asian Markets

Retrieved on: 
Wednesday, June 2, 2021
Pharmaceutical, Health, Clinical trials, Lyra, Lyr

Upon commercialization on a region-by-region basis, Lyra also will be entitled to receive low double-digit royalties based on net sales of LYR-210 in the licensed territories.

Key Points: 
  • Upon commercialization on a region-by-region basis, Lyra also will be entitled to receive low double-digit royalties based on net sales of LYR-210 in the licensed territories.
  • LianBio will be responsible for the clinical development and commercialization of LYR-210 in the licensed territories, and Lyra will retain all rights to LYR-210 in all other geographies.
  • The LianBio team has deep expertise in drug development and is well positioned to successfully commercialize LYR-210 in these Asian territories.
  • The introduction of our novel, integrated ENT drug and delivery solution to the large patient populations in Asian markets supports our planned global commercialization strategy.

Lyra Therapeutics to Present at the William Blair 41st Annual Growth Stock Conference

Retrieved on: 
Tuesday, June 1, 2021
Health, Medical devices, Other Health, Managed care, General Health, Pharmaceutical, Biotechnology, Lyr, Otorhinolaryngology

The live audio webcast for this conference can be accessed from the Investor Relations section of the company's website at www.lyratherapeutics.com .

Key Points: 
  • The live audio webcast for this conference can be accessed from the Investor Relations section of the company's website at www.lyratherapeutics.com .
  • The webcast replay will be available after the conclusion of the live presentation for approximately 30 days.
  • Lyra Therapeutics, Inc. is a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose and throat (ENT) diseases.
  • Lyra is also developing LYR-220 for CRS patients who have undergone a prior surgery and have persistent disease.

Lyra Therapeutics To Present At The Jefferies Virtual Healthcare Conference

Retrieved on: 
Monday, May 24, 2021
Biotechnology, Pharmaceutical, Health, Other Health, Lyr, Otorhinolaryngology

The live audio webcast for this conference can be accessed from the Investor Relations section of the company's website at www.lyratherapeutics.com .

Key Points: 
  • The live audio webcast for this conference can be accessed from the Investor Relations section of the company's website at www.lyratherapeutics.com .
  • The webcast replay will be available after the conclusion of the live presentation for approximately 30 days.
  • Lyra Therapeutics, Inc. is a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose and throat (ENT) diseases.
  • Lyra is also developing LYR-220 for CRS patients who have undergone a prior surgery and have persistent disease.

Lyra Therapeutics Reports First Quarter 2021 Financial Results and Provides Corporate Update

Retrieved on: 
Tuesday, May 11, 2021
Pharmaceutical, Health, Clinical trials, Medical devices, Astronomy, Lyra, Lyr, Patient, Applied sciences

Further, LYR-210 decreased ethmoid opacification at week 24 as well as reduced patient need for rescue medication.

Key Points: 
  • Further, LYR-210 decreased ethmoid opacification at week 24 as well as reduced patient need for rescue medication.
  • Previously, Lyra announced positive topline from the data in December 2020.
  • Lyra is also developing LYR-220 for CRS patients who have undergone a prior surgery and have persistent disease.
  • Any such forward-looking statements represent management\xe2\x80\x99s estimates as of the date of this press release.

Lyra Therapeutics to Present at the BofA Securities 2021 Virtual Health Care Conference

Retrieved on: 
Thursday, May 6, 2021
Professional services, Health, Medical devices, Finance, Clinical trials, Pharmaceutical, Biotechnology, Byzantine music, Greek musical instruments, Musical instruments, Music, Astronomy, Lyra, Lyr, Forward-looking statement, Byzantine lyra, She-Hulk, Cretan lyra

b"Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose and throat (ENT) diseases, today announced that Maria Palasis, Ph.D., Lyra\xe2\x80\x99s President and Chief Executive Officer, will present at the BofA Securities 2021 Virtual Health Care Conference on Thursday, May 13, 2021 at 4:15 p.m. ET.\nInterested parties can access the live audio webcast for this conference from the Investor Relations section of the company's website at www.lyratherapeutics.com .

Key Points: 
  • b"Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose and throat (ENT) diseases, today announced that Maria Palasis, Ph.D., Lyra\xe2\x80\x99s President and Chief Executive Officer, will present at the BofA Securities 2021 Virtual Health Care Conference on Thursday, May 13, 2021 at 4:15 p.m. ET.\nInterested parties can access the live audio webcast for this conference from the Investor Relations section of the company's website at www.lyratherapeutics.com .
  • Lyra is also developing LYR-220 for CRS patients who have undergone a prior surgery and have persistent disease.
  • All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including statements regarding the company\xe2\x80\x99s development of LYR-210 and LYR-220.
  • Any such forward-looking statements represent management\xe2\x80\x99s estimates as of the date of this press release.

Lyra Therapeutics to Report First Quarter 2021 Financial Results and Provide Corporate Update

Retrieved on: 
Tuesday, April 27, 2021
Health, Other Science, Clinical trials, General Health, Pharmaceutical, Science, Astronomy, Lyra, Lyr, Conference call, Lyra, Applied sciences

Lyra will host a corresponding conference call and live webcast at 4:30 p.m.

Key Points: 
  • Lyra will host a corresponding conference call and live webcast at 4:30 p.m.
  • ET on the same day to discuss the results and provide a corporate update.\nTo access the live call by phone, dial (833) 519-1249 (domestic) or (914) 800-3822 (international) and use the conference ID: 3067707.
  • To access a live webcast of the call, please visit the Investor Relations section of the Lyra Therapeutics website at www.lyratherapeutics.com .
  • Lyra is also developing LYR-220 for CRS patients who have undergone a prior surgery and have persistent disease.

Lyra Therapeutics Presents Positive Full Data Set from LANTERN Phase 2 Study of LYR-210 at COSM 2021 Virtual

Retrieved on: 
Sunday, April 11, 2021
Pharmaceutical, Health, Clinical trials, Astronomy, Lyra, Lyr, Sinusitis, Cretan lyra

Lyra reported positive topline data from the LANTERN study in December 2020.\nThe COSM oral presentation, titled Long-acting implantable corticosteroid matrix for chronic rhinosinusitis: Results of LANTERN Phase 2 randomized controlled study, contains the full 24-week data set from the company\xe2\x80\x99s Phase 2 clinical trial of LYR-210.

Key Points: 
  • Lyra reported positive topline data from the LANTERN study in December 2020.\nThe COSM oral presentation, titled Long-acting implantable corticosteroid matrix for chronic rhinosinusitis: Results of LANTERN Phase 2 randomized controlled study, contains the full 24-week data set from the company\xe2\x80\x99s Phase 2 clinical trial of LYR-210.
  • I believe today\xe2\x80\x99s data supports LYR-210\xe2\x80\x99s ability to provide up to 24 weeks of effective symptom relief,\xe2\x80\x9d said Robert Kern, MD, Chief Medical Officer of Lyra Therapeutics.
  • \xe2\x80\x9cLYR-210 is designed to provide continuous and consistent steroid treatment directly to diseased tissue and, additionally, eliminate patient compliance challenges.
  • Lyra is also developing LYR-220 for CRS patients who have undergone a prior surgery and have persistent disease.

Lyra Therapeutics to Present LANTERN Phase 2 Study Results for LYR‑210 in Oral Presentation at COSM 2021 Virtual

Retrieved on: 
Monday, March 29, 2021
FDA, Health, Other Health, Clinical trials, Pharmaceutical, Biotechnology, Lyra, Lyr, Forward-looking statement, Cretan lyra, Music, Articles

The oral presentation for LYR-210 will be featured in a COSM 2021 Virtual session on April 11.

Key Points: 
  • The oral presentation for LYR-210 will be featured in a COSM 2021 Virtual session on April 11.
  • A clinical presentation of this data will be made available on Lyras website .
  • Lyra is also developing LYR-220 for CRS patients who have undergone a prior surgery and have persistent disease.
  • This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.